Terminated PHASE3 INTERVENTIONAL NCT00016341

Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer

Randomized Phase III Crossover Trial of Chemotherapy (Doxorubicin/Cisplatin/Paclitaxel and G-CSF) Versus Hormonal Therapy (Tamoxifen/Megestrol Acetate) in Patients With Stage III & IV or Recurrent Endometrial Cancer

Sponsor: Gynecologic Oncology Group

Conditions Endometrial Cancer

Interventions cisplatin doxorubicin hydrochloride filgrastim megestrol acetate paclitaxel tamoxifen citrate

Updated 7 times since 2017 Last updated: Apr 10, 2013 Started: May 31, 2001 Primary completion: Oct 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Gynecologic Oncology Group

More terminations from Gynecologic Oncology Group

Other Endometrial Cancer trials with similar outcome

Browse all Endometrial Cancer trials

This PHASE3 trial investigates Endometrial Cancer and is currently terminated or withdrawn. Gynecologic Oncology Group leads this study, which shows 7 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Feb 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Feb 2021 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

May 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gynecologic Oncology Group
National Cancer Institute (NCI)

Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Albany, United States , Birmingham, United States , Boston, United States , Brooklyn, United States , Buffalo, United States , Burlington, United States , Calgary, Canada , Camden, United States , Chapel Hill, United States and 35 more locations